HC Wainwright Has Negative Outlook for AQST FY2025 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a report issued on Monday, November 10th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.63) per share for the year, down from their previous estimate of ($0.61). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q4 2025 earnings at ($0.12) EPS.

Several other analysts also recently issued reports on AQST. Citigroup reiterated an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Piper Sandler boosted their target price on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Oppenheimer upped their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. JMP Securities lifted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a research report on Thursday, October 9th. Finally, Zacks Research upgraded shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $10.00.

Aquestive Therapeutics Trading Down 1.9%

Shares of NASDAQ:AQST opened at $5.58 on Wednesday. The stock has a market capitalization of $680.76 million, a PE ratio of -7.86 and a beta of 1.79. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $7.55. The firm has a fifty day moving average price of $5.99 and a 200 day moving average price of $4.34.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $12.81 million for the quarter, compared to analysts’ expectations of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Aquestive Therapeutics by 30.8% in the 3rd quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock valued at $31,651,000 after buying an additional 1,333,627 shares in the last quarter. Geode Capital Management LLC raised its position in Aquestive Therapeutics by 16.2% in the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock worth $6,545,000 after purchasing an additional 276,295 shares in the last quarter. Pale Fire Capital SE lifted its stake in Aquestive Therapeutics by 25.5% during the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock worth $5,549,000 after purchasing an additional 340,767 shares during the period. Commonwealth Equity Services LLC acquired a new stake in Aquestive Therapeutics during the third quarter valued at approximately $5,918,000. Finally, Sio Capital Management LLC grew its stake in shares of Aquestive Therapeutics by 141.9% in the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock valued at $3,136,000 after purchasing an additional 555,860 shares during the period. Institutional investors own 32.45% of the company’s stock.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Peter E. Boyd sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total value of $70,000.00. Following the completion of the transaction, the insider owned 268,323 shares of the company’s stock, valued at $1,878,261. This represents a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Barber sold 91,343 shares of the firm’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $6.03, for a total value of $550,798.29. Following the completion of the sale, the chief executive officer owned 923,430 shares of the company’s stock, valued at $5,568,282.90. This represents a 9.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 276,770 shares of company stock valued at $1,692,203 in the last ninety days. 8.35% of the stock is owned by corporate insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.